Last updated: July 31, 2026
Berinert is CSL Behring’s plasma-derived C1 esterase inhibitor for treating acute hereditary angioedema attacks. Its FDA-approved role is established, but its commercial position is under pressure from oral and long-acting prophylactic therapies. Berinert remains relevant for rapid on-demand treatment, hospital use, pediatric practice, and patients who require a C1 inhibitor rather than a kallikrein-targeted product.
The main commercial risks are competition from Takhzyro, Orladeyo, Haegarda, Firazyr, Ruconest and newer HAE therapies; limited public disclosure of Berinert-specific revenue; and the absence of a large new clinical indication that would materially expand its market.
What is Berinert and how does it work?
Berinert contains human plasma-derived C1 esterase inhibitor, also known as C1-INH. It replaces deficient or dysfunctional C1-INH in patients with hereditary angioedema caused primarily by SERPING1 mutations.
C1-INH regulates the complement, contact, coagulation and fibrinolytic systems. In HAE, inadequate C1-INH activity increases bradykinin generation, producing episodic swelling of the skin, gastrointestinal tract, larynx and other tissues.
In the United States, Berinert is approved for treatment of acute abdominal, facial or laryngeal HAE attacks in adults and adolescents. The labeled dose is 20 IU/kg administered by intravenous infusion. It is not the principal FDA-approved long-term prophylaxis product in the United States. [1]
Berinert product profile
| Attribute |
Berinert |
| Active ingredient |
Human C1 esterase inhibitor |
| Product type |
Plasma-derived biologic |
| Sponsor and manufacturer |
CSL Behring |
| U.S. indication |
Treatment of acute abdominal, facial or laryngeal HAE attacks |
| Route |
Intravenous |
| U.S. dose |
20 IU/kg |
| Disease |
Hereditary angioedema due to C1-INH deficiency |
| FDA approval |
2009 |
| Regulatory category |
Biologic license application product |
| Principal competitors |
Firazyr, Ruconest, Takhzyro, Orladeyo, Haegarda, Kalbitor |
What clinical trials support Berinert?
Berinert’s core efficacy evidence came from the IMPACT program, which evaluated intravenous C1-INH in acute HAE attacks.
IMPACT1 and IMPACT2
IMPACT1 was a randomized, placebo-controlled phase 3 study evaluating Berinert at 10 IU/kg and 20 IU/kg. The 20 IU/kg dose produced faster relief than placebo and became the basis for the U.S. dosing regimen. The study evaluated time to beginning of relief and time to complete relief across abdominal, facial and other peripheral attacks. [2]
IMPACT2 was an open-label extension study that assessed repeated treatment of acute attacks. It provided longer-term evidence on effectiveness and tolerability across multiple attacks and supported the use of weight-based repeat treatment in clinical practice. [3]
| Trial |
Phase |
Design |
Primary purpose |
Commercial relevance |
| IMPACT1 |
3 |
Randomized, placebo-controlled |
Establish efficacy and dose |
Supported 20 IU/kg approval dose |
| IMPACT2 |
3/extension |
Open-label, repeated treatment |
Evaluate repeated acute-use treatment |
Supported durability and real-world usability |
| Postmarketing studies |
Various |
Observational and safety-focused |
Monitor plasma-derived C1-INH use |
Reinforce established safety profile |
The pivotal evidence is mature. Berinert does not currently depend on an uncompleted pivotal trial for its core U.S. indication.
What is the current Berinert clinical-trial outlook?
The active development outlook is limited compared with newer HAE products. Berinert’s clinical value is well established for acute attacks, while current industry research is concentrated on subcutaneous, oral and gene-based approaches.
Clinical development priorities in HAE have shifted toward:
- Long-term prophylaxis with less frequent dosing.
- Oral kallikrein inhibition.
- Subcutaneous and self-administered products.
- Gene therapy and durable correction of SERPING1-related disease.
- Treatment of patients with normal C1-INH levels and other HAE subtypes.
- Pediatric and adolescent treatment strategies.
- Comparative effectiveness and treatment burden.
Berinert may still appear in observational studies, registries, pharmacovigilance research and comparative HAE analyses. Those studies are unlikely to change the product’s regulatory status unless CSL Behring pursues a new indication, such as expanded prophylaxis or a new age group.
What is the FDA regulatory and exclusivity status of Berinert?
The FDA approved Berinert in October 2009 through a biologics license application. Its U.S. approval covers acute HAE attacks rather than routine long-term prophylaxis. [1]
Because Berinert is a biologic, its U.S. competitive framework is governed primarily by the Public Health Service Act and the biosimilar pathway, not by the conventional small-molecule generic pathway under Hatch-Waxman.
Orange Book and Purple Book status
Berinert is not a conventional Orange Book small-molecule product. Biologic reference products and biosimilar-related information are tracked through the FDA Purple Book framework. [4]
A competing product would generally require:
- An independent biologics license application; or
- A biosimilar or interchangeable biosimilar application, if the product and reference-product characteristics support that pathway.
C1-INH products are difficult to duplicate because they are plasma-derived, compositionally complex and dependent on donor plasma, purification, viral inactivation, analytical characterization and supply-chain controls.
Exclusivity timeline
| Event |
Date or status |
| FDA approval |
2009 |
| Orphan-drug period |
Historically applied to the approved orphan indication |
| Conventional biologic reference exclusivity |
Expired based on the original approval timeline |
| Current competition |
Primarily branded HAE products and alternative biologics |
| Generic entry |
Not applicable in the conventional tablet or capsule sense |
| Biosimilar risk |
Legally possible but operationally difficult |
The expiry of regulatory exclusivity does not mean immediate competitive entry. Manufacturing complexity, plasma sourcing and clinical-development requirements remain significant barriers.
What patents protect Berinert?
Berinert’s commercial protection is more likely to depend on manufacturing know-how, plasma sourcing, quality systems, regulatory history and supply reliability than on a single late-expiring formulation patent.
Publicly available product information does not indicate that Berinert has an Orange Book-style patent listing that would generate a standard Paragraph IV litigation pathway. Patent scope may exist around C1-INH purification, stabilization, viral inactivation, formulation, container systems and manufacturing processes, but those rights must be evaluated patent by patent across jurisdictions.
Why Berinert has manufacturing-related protection
A plasma-derived biologic requires control over:
- Donor eligibility and plasma collection.
- Fractionation and purification.
- Viral clearance and pathogen reduction.
- Protein recovery and activity.
- Batch consistency.
- Cold-chain logistics.
- Release testing and pharmacopoeial compliance.
These capabilities can delay competition even after core patent or exclusivity periods end. A biosimilar developer would need to demonstrate high similarity to a complex reference product and establish a commercially reliable plasma and manufacturing network.
Which companies are challenging Berinert in the HAE market?
Berinert faces competition from products that differ in mechanism, route, dosing frequency and treatment role.
| Product |
Company |
Mechanism |
Primary role |
| Takhzyro |
Takeda |
Plasma kallikrein inhibitor |
Long-term prophylaxis |
| Orladeyo |
BioCryst |
Oral plasma kallikrein inhibitor |
Long-term prophylaxis |
| Haegarda |
CSL Behring |
Subcutaneous C1-INH |
Long-term prophylaxis |
| Firazyr |
Takeda |
Bradykinin B2 receptor antagonist |
Acute treatment |
| Ruconest |
Pharming |
Recombinant C1-INH |
Acute treatment |
| Kalbitor |
Takeda |
Plasma kallikrein inhibitor |
Acute treatment |
| Donidalorsen |
Ionis Pharmaceuticals |
Antisense therapy targeting prekallikrein |
Investigational prophylaxis |
| Garadacimab |
CSL |
Factor XIIa inhibitor |
Investigational or recently regulated prophylaxis, depending on jurisdiction |
Takhzyro and Orladeyo create the largest strategic pressure because they address preventive treatment and reduce reliance on rescue therapy. Haegarda competes more directly with Berinert’s C1-INH biology but uses subcutaneous administration for prophylaxis.
Berinert retains a role when physicians prefer replacement therapy, when an acute attack requires intravenous C1-INH, or when patients have treatment-specific contraindications or access limitations.
How does Berinert compare with Takhzyro, Orladeyo and Firazyr?
| Criterion |
Berinert |
Takhzyro |
Orladeyo |
Firazyr |
| Treatment role |
Acute treatment |
Prophylaxis |
Prophylaxis |
Acute treatment |
| Mechanism |
C1-INH replacement |
Kallikrein inhibition |
Oral kallikrein inhibition |
Bradykinin B2 blockade |
| Administration |
IV |
Subcutaneous |
Oral |
Subcutaneous |
| Main advantage |
Established replacement therapy |
Long-acting prevention |
Oral administration |
Convenient rescue treatment |
| Main limitation |
IV infusion and attack-based use |
Injection and cost |
Daily oral dosing and drug-interaction considerations |
Does not prevent attacks |
| Direct Berinert threat |
Moderate |
High for prophylaxis |
High for prophylaxis |
High for acute treatment |
Berinert’s strongest competitive position is in acute C1-INH replacement. Its weaker position is chronic prevention, where subcutaneous and oral products reduce treatment burden.
What is the Berinert market size and revenue outlook?
CSL Behring does not publicly report Berinert revenue as a separate product line in its standard financial disclosures. CSL reports broader business segments and product categories, which prevents a precise public calculation of Berinert sales. [5]
The global HAE therapeutics market is commonly estimated in the multibillion-dollar range, with growth driven by diagnosis, prophylaxis adoption, expanded access and new mechanisms. Public market forecasts vary because they use different definitions of HAE treatment, geographic coverage and product inclusion.
A practical commercial model is:
| Market measure |
2023 estimate |
2030 base case |
Implied trend |
| Global HAE therapeutics market |
Approximately $4 billion to $5 billion |
Approximately $7 billion to $9 billion |
Mid- to high-single-digit growth |
| Acute-treatment segment |
Approximately $1.5 billion to $2 billion |
Approximately $2 billion to $3 billion |
Moderate growth |
| Prophylaxis segment |
Approximately $2 billion to $3 billion |
Approximately $5 billion to $6 billion |
Faster growth |
| Berinert-specific revenue |
Not separately disclosed |
Not publicly forecast |
Likely stable to declining share |
These figures are an analytical market model, not CSL Behring guidance. The market should expand as more patients receive preventive therapy, but Berinert’s share is likely to decline unless CSL expands the product’s indication or uses it in combination with a differentiated delivery system.
Revenue exposure
Berinert’s revenue exposure is linked to:
- The number of diagnosed HAE patients.
- Acute attack frequency.
- Hospital and emergency-department utilization.
- Physician preference for C1-INH replacement.
- Availability of competing rescue products.
- Uptake of long-term prophylaxis.
- Plasma collection volumes and manufacturing capacity.
- Reimbursement and specialty-pharmacy access.
The product’s mature profile limits clinical-development risk, while plasma dependence creates supply and cost exposure.
What generic or biosimilar launch risks exist for Berinert?
A conventional generic launch is not the principal threat. The more credible risks are:
- A competing C1-INH biologic with biosimilar or reference-product positioning.
- A recombinant C1-INH product with improved supply scalability.
- Oral or subcutaneous products replacing rescue or prophylaxis use.
- Hospital protocols that favor non-C1-INH acute therapies.
- Payer management that directs patients toward lower-cost alternatives.
- New therapies that reduce attack frequency and therefore reduce demand for rescue doses.
A biosimilar competitor would face technical and commercial barriers. Plasma-derived products can show lot-to-lot variability, and biosimilar development requires extensive analytical comparability, clinical pharmacology and immunogenicity assessment. The most immediate competitive threat is therefore therapeutic substitution, not a traditional generic cliff.
What patent litigation and Paragraph IV challenges affect Berinert?
No major public Paragraph IV litigation pattern defines Berinert’s market. Paragraph IV challenges generally apply to patents listed for small-molecule drugs in the Orange Book. Berinert is a biologic and does not have the same automatic patent-litigation structure.
Potential disputes could instead involve:
- Patent infringement claims over C1-INH purification.
- Formulation and stabilization technology.
- Recombinant or plasma-derived C1-INH manufacturing.
- Biosimilar regulatory exclusivity.
- Trade secrets and process know-how.
- Trademark and product substitution issues.
The absence of a prominent Paragraph IV dispute reduces the likelihood of a near-term patent-driven generic launch. It does not eliminate competition from independently developed HAE biologics.
What licensing deals affect Berinert?
Berinert is primarily associated with CSL Behring’s internal plasma-derived biologics platform. Public disclosures do not identify a major recent licensing transaction that materially changes Berinert’s commercial rights or creates a near-term co-commercialization event.
CSL’s broader HAE strategy includes internal development and commercialization of C1-INH products, including Haegarda, and development of next-generation HAE therapies. The commercial logic is to maintain coverage across acute treatment, prophylaxis and emerging non-C1-INH mechanisms.
What are the 2025-2030 Berinert launch scenarios?
Base case
Berinert remains approved and commercially available for acute HAE treatment. Sales decline gradually as preventive therapies reduce attack frequency and as acute competitors gain share. CSL maintains the product through established manufacturing and physician familiarity.
Upside case
Berinert benefits from:
- Increased diagnosis of HAE.
- Expanded use in adolescents and specialty centers.
- Supply shortages affecting competitors.
- Greater physician preference for C1-INH replacement.
- Regulatory or label expansion into additional prophylaxis settings.
Downside case
Sales decline faster because:
- Takhzyro and Orladeyo capture more prophylaxis patients.
- Acute therapies become easier to self-administer.
- New oral or long-acting products reduce rescue demand.
- Payers impose step edits and preferred-product rules.
- A competing C1-INH or recombinant product gains share.
The most probable outcome is continued clinical relevance with declining relative market share.
Key Takeaways
- Berinert is an FDA-approved plasma-derived C1-INH for acute HAE attacks.
- Its pivotal evidence comes from the IMPACT1 and IMPACT2 studies.
- The product has a mature clinical and regulatory profile.
- Berinert is not subject to a conventional Orange Book Paragraph IV generic challenge.
- Biosimilar competition is possible but technically and commercially difficult.
- Takhzyro and Orladeyo are the main strategic threats because they target long-term prophylaxis.
- Haegarda is CSL Behring’s more direct C1-INH prophylaxis product.
- CSL does not separately disclose Berinert revenue.
- The HAE market is likely to grow through 2030, while Berinert’s share is likely to remain flat or decline.
- Manufacturing know-how, plasma supply and regulatory experience provide meaningful barriers beyond patents.
Frequently Asked Questions
Is Berinert still FDA approved?
Yes. Berinert remains FDA approved for treatment of acute abdominal, facial or laryngeal HAE attacks in adults and adolescents.
Is Berinert a biosimilar?
No. Berinert is the original CSL Behring plasma-derived C1-INH product marketed under its U.S. biologics approval.
Can Berinert be used for long-term HAE prophylaxis?
The U.S. Berinert label is directed to treatment of acute attacks. Haegarda, another CSL Behring C1-INH product, is the company’s U.S. subcutaneous prophylaxis product.
Does Berinert have an Orange Book patent?
Berinert is a biologic rather than a conventional small-molecule Orange Book product. Relevant biologic competition is evaluated under the Purple Book and Public Health Service Act framework.
What drug is most likely to replace Berinert?
Replacement will vary by use. Firazyr and Ruconest compete in acute treatment, while Takhzyro and Orladeyo are stronger substitutes for patients using preventive therapy.
References
-
U.S. Food and Drug Administration. (2023). Berinert prescribing information. CSL Behring LLC.
-
Craig, T. J., Levy, R. J., Wasserman, R. L., Bewtra, A. K., Hurewitz, D., Obtulowicz, K., Reshef, A., Ritchie, B., Wunderlich, S., & Moldovan, R. (2009). Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. Journal of Allergy and Clinical Immunology, 124(4), 801-808.
-
Zuraw, B. L., Busse, P. J., White, M., Jacobs, J., Lumry, W., Baker, J., Craig, T., Grant, J. A., Hurewitz, D., Bielory, L., et al. (2010). Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology, 126(4), 821-827.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
-
CSL Limited. (2024). Annual report 2024. CSL Limited.
-
ClinicalTrials.gov. (n.d.). IMPACT and Berinert clinical studies. U.S. National Library of Medicine.
